Luspatercept in Lower-Risk MDS

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Data from the following clinical trials are discussed:

  • 3098: Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
  • 4408: Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
  • 1774: Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial
  • 389: Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
Related Videos
Jorge E. Cortes, MD
Julie Renee Brahmer, MD
Bradley W. Christensen, MD
Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Aaron Gerds, MD, an expert on myeloproliferative neoplasms
Expert on AML
Related Content